Skip to content

Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with ARBs undergoing CABG

Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201804003249274
Enrollment
100
Registered
2018-03-25
Start date
2017-11-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System vasoplegic syndrome, coronary artery bypass graft surgery

Interventions

terlipressin infusion

Sponsors

Ain Shams University Hospitals
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients on angiotensin II receptor antagonist losartan for at least 4 weeks before operation normal or mild impairment of left ventricular function (EF ¿ 40 by transthoracic echocardiography).

Exclusion criteria

Exclusion criteria: Patients with a critical preoperative state were excluded from the study, including patients with intractable ventricular arrhythmias, previous aborted sudden cardiac death, preoperative mechanical ventilation, preoperative use of inotropes, preoperative use of intra-aortic balloon counter-pulsation, recent myocardial infarction. Patients with previous cardiac surgery, associated valvular heart disease, chronic lung disease, extra-cardiac arteriopathy, moderate to severe renal impairment were also excluded.

Design outcomes

Primary

MeasureTime frame
Incidence of vasoplegic syndrome

Secondary

MeasureTime frame
inotropic score ;vasopressor dependency index ;Hemodynamic parameters: mean arterial blood pressure, central venous pressure, Cardiac index, systemic vascular resistance index.

Countries

Egypt

Contacts

Public ContactMohamed Saleh

Lecturer of anesthesia

drsalehm2002@hotmail.com+201227761463

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 19, 2026